RICHLAND, WASHINGTON – September 28, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. (Viewpoint) a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents.

The patent awards Cellular Engineering Technologies the intellectual property to develop, manufacture and commercialize induced pluripotent stem cells that are virus-free and carry a much lower cancer risk

CORALVILLE, Iowa, Nov. 16, 2021 /PRNewswire/ -- VIDA Diagnostics, Inc. (VIDA) is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal. The cloud-based VIDA Intelligence Portal (VIP) streamlines challenges often associated with imaging in trials such as site onboarding, staff training, image data management, and data quality. Leveraging a powerful AI engine, the portal automates cumbersome and time sensitive tasks such as subject anonymization and quality control workflow processes.

Millions of dollars in federal funding helped leverage private investment in a growing Corridor-based radiopharmaceutical company, expanding its economic impact and attracting top talent to Iowa.